Atrinsic (PTIX) Competitors $2.93 -0.14 (-4.56%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$2.84 -0.09 (-3.07%) As of 08/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PTIX vs. APLM, HCWB, CDIO, PMCB, NKGN, ACXP, JBIO, PLRZ, PPBT, and GTBPShould you be buying Atrinsic stock or one of its competitors? The main competitors of Atrinsic include Apollomics (APLM), HCW Biologics (HCWB), Cardio Diagnostics (CDIO), Nuvilex (PMCB), NKGen Biotech (NKGN), Acurx Pharmaceuticals (ACXP), Jade Biosciences (JBIO), Polyrizon (PLRZ), Purple Biotech (PPBT), and GT Biopharma (GTBP). These companies are all part of the "pharmaceutical products" industry. Atrinsic vs. Its Competitors Apollomics HCW Biologics Cardio Diagnostics Nuvilex NKGen Biotech Acurx Pharmaceuticals Jade Biosciences Polyrizon Purple Biotech GT Biopharma Apollomics (NASDAQ:APLM) and Atrinsic (NASDAQ:PTIX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership. Does the media favor APLM or PTIX? In the previous week, Apollomics and Apollomics both had 1 articles in the media. Atrinsic's average media sentiment score of 1.88 beat Apollomics' score of 1.87 indicating that Atrinsic is being referred to more favorably in the news media. Company Overall Sentiment Apollomics Very Positive Atrinsic Very Positive Which has higher valuation & earnings, APLM or PTIX? Atrinsic has lower revenue, but higher earnings than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApollomics$1.49M4.02-$53.86MN/AN/AAtrinsicN/AN/A-$5.53M-$13.11-0.22 Do institutionals and insiders believe in APLM or PTIX? 19.1% of Apollomics shares are owned by institutional investors. Comparatively, 8.0% of Atrinsic shares are owned by institutional investors. 35.0% of Atrinsic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is APLM or PTIX more profitable? Apollomics' return on equity of 0.00% beat Atrinsic's return on equity.Company Net Margins Return on Equity Return on Assets ApollomicsN/A N/A N/A Atrinsic N/A -860.52%-354.19% Which has more volatility & risk, APLM or PTIX? Apollomics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Atrinsic has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. SummaryApollomics beats Atrinsic on 5 of the 8 factors compared between the two stocks. Get Atrinsic News Delivered to You Automatically Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTIX vs. The Competition Export to ExcelMetricAtrinsicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.81M$3.10B$5.67B$9.82BDividend YieldN/A2.23%3.79%4.08%P/E Ratio-0.2220.3830.5825.12Price / SalesN/A368.96464.24116.42Price / CashN/A42.3037.4059.05Price / Book1.498.659.096.18Net Income-$5.53M-$54.65M$3.25B$264.89M7 Day Performance3.53%6.58%7.42%4.22%1 Month Performance-15.07%7.54%5.50%2.02%1 Year Performance-60.59%13.73%30.67%24.22% Atrinsic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTIXAtrinsic1.0004 of 5 stars$2.93-4.6%N/A-61.2%$1.81MN/A-0.222Positive NewsGap UpAPLMApollomics0.4313 of 5 stars$5.81+2.1%N/A-63.2%$6.39M$1.49M0.0045Gap UpHCWBHCW Biologics2.3378 of 5 stars$4.40-5.3%$35.00+696.4%-79.6%$6.33M$2.57M-0.1940News CoverageShort Interest ↑Gap DownCDIOCardio Diagnostics2.7982 of 5 stars$3.63+4.3%$60.00+1,552.9%-71.4%$6.32M$40K0.001News CoverageEarnings ReportAnalyst UpgradeShort Interest ↑Gap UpPMCBNuvilex1.7398 of 5 stars$0.92+5.0%N/A-52.8%$6.31MN/A1.244Earnings ReportHigh Trading VolumeNKGNNKGen Biotech0.2335 of 5 stars$0.14-17.6%N/A-84.0%$6.29MN/A-0.03N/AGap DownACXPAcurx Pharmaceuticals3.026 of 5 stars$4.06-9.4%$31.00+663.5%-87.5%$6.25MN/A-0.293News CoverageEarnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionGap DownJBIOJade Biosciences2.1307 of 5 stars$7.32-1.1%$15.00+104.9%N/A$6.15MN/A-0.1220News CoveragePositive NewsEarnings ReportAnalyst ForecastGap UpPLRZPolyrizonN/A$1.00-2.9%N/AN/A$5.99MN/A0.00N/ANews CoverageGap DownPPBTPurple Biotech2.2219 of 5 stars$2.26+2.7%$33.00+1,360.8%N/A$5.85MN/A-5.3820Gap DownGTBPGT Biopharma2.6192 of 5 stars$1.69-2.9%$11.00+550.9%-41.7%$5.53MN/A-0.308News CoverageEarnings Report Related Companies and Tools Related Companies Apollomics Alternatives HCW Biologics Alternatives Cardio Diagnostics Alternatives Nuvilex Alternatives NKGen Biotech Alternatives Acurx Pharmaceuticals Alternatives Jade Biosciences Alternatives Polyrizon Alternatives Purple Biotech Alternatives GT Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTIX) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atrinsic Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atrinsic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access